A plan by Covidien to buy back $3 billion of its stock has been approved by the company's board, a move expected to benefit shareholders over the short term. In August 2011, the company also initiated a similar repurchase program, worth $2 billion.
Covidien to repurchase $3B more in company shares
SmartBrief Job Listings for Health Care
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
Meridian Health Plan